The neuronal PAS domain 3 (NPAS3) gene encodes a neuronal transcription factor that is implicated in psychiatric disorders by the identification of a human chromosomal translocation associated with schizophrenia and a mouse knockout model with behavioural and hippocampal neurogenesis defects. To determine its contribution to the risk of psychiatric illness in the general population, we genotyped 70 single-nucleotide polymorphisms across the NPAS3 gene in 368 individuals with bipolar disorder, 386 individuals with schizophrenia and 455 controls. Modestly significant single-marker and global and individual haplotypes were identified in four discrete regions of the gene. The presence of both risk and protective haplotypes at each of these four regions indicated locus and allelic heterogeneity within NPAS3 and suggested a model whereby interactions between variants across the gene might contribute to susceptibility to illness. This was supported by predicting the most likely haplotype for each individual at each associated region and then calculating an NPAS3-mediated 'net genetic load' value. This value differed significantly from controls for both bipolar disorder (P = 0.0000010) and schizophrenia (P = 0.0000012). Logistic regression analysis also confirmed the combinatorial action of the four associated regions on disease risk. In addition, sensitivity/specificity plots showed that the extremes of the genetic loading distribution possess the greatest predictive power-a feature suggesting multiplicative allele interaction. These data add to recent evidence that the combinatorial analysis of a number of relatively small effect size haplotypes may have significant power to predict an individual's risk of a complex genetic disorder such as psychiatric illness.
Introduction
The nature of the genetic architecture of complex diseases such as schizophrenia and bipolar disorder is currently poorly understood but is a critical issue, with clear implications for the application of appropriate gene-hunting strategies and genetic risk assessment. The gene-hunting methodology selected (for example, large family-based linkage, case-control association, re-sequencing, and so on) and the DNA sample set to which it is applied (sporadic or familial cases) will determine the class of mutation that can be identified and the success rate. The current literature suggests that candidate disease gene mutations exist as either rare, highly penetrant, predominantly familial forms or common, low penetrance, population risk forms, but it is also likely that many mutations will exist somewhere on a spectrum between these extremes. [1] [2] [3] [4] [5] We have recently reviewed the evidence supporting the candidacy of neuronal PAS domain 3 (NPAS3) in the aetiology of psychiatric disorders such as schizophrenia and bipolar disorder. 6 In brief, NPAS3 was identified as a disease candidate through the study of a balanced chromosomal translocation, t(9,14)(q34.2;q13), associated with schizophrenia and learning disability (also known as mental retardation in the United States) in a mother and daughter. The breakpoint on chromosome 14 directly disrupted the NPAS3 gene leading to probable haploinsufficiency. 7, 8 A mouse strain with a knockout of the Npas3 gene orthologue exhibited abnormal performance in behavioural tests and a hippocampal neurogenesis deficit, 9-11 the latter being a potential marker for psychiatric pathology. 12, 13 The gene itself encodes a neuronally expressed transcription factor of the basic helix-loop-helix class 14 and, by inference from other related proteins, most likely transduces cellular environmental changes into transcriptional response. Recently, NPAS3 was also identified as one of a number genes associated with genetic vulnerability to addiction. 15 The NPAS3 cytogenetic findings suggest that structural disruption of one allele can give rise to highly penetrant and dominantly inherited psychiatric illness. This implies the possibility that such mutations would give rise to positive linkage findings. Several instances of linkage to chromosome 14q13 have indeed been reported for schizophrenia and bipolar disorder. [16] [17] [18] However, the possibility that lower penetrance, common polymorphic alleles within NPAS3 contribute towards the risk of nonfamilial/sporadic schizophrenia or bipolar disorder at the population level has not been tested previously. We have therefore carried out a case-control association study employing a relatively large DNA sample sets and linkage disequilibrium (LD)-based tag singlenucleotide polymorphism (SNP) coverage over the NPAS3 gene. Four regions within the NPAS3 gene were identified with significant P-value associations at the single-marker and haplotype resolutions. Both common risk-increasing and protective haplotypes were identified with clear frequency differences between the case and control groups. We demonstrated that these risk and protective effects act combinatorially, potentially multiplicatively, to determine NPAS3 gene-wide susceptibility. This was quantified by calculating a 'net genetic load' that showed statistically significant differences between case and control populations and, moreover, appeared to be near diagnostic for individuals with extreme net genetic load values.
Materials and methods

Association study
Single-nucleotide polymorphism marker selection was achieved by analysing the public International HAPMAP Project 19 genotyping data (release no. 7) from the CEU population (Utah residents with ancestry from northern and western Europe) in the Haploview v. 2.5 application. 20 LD blocks across the NPAS3 locus were defined using Haploview's 'solid spine of LD' method with D 0 values greater than 0.8. Adjacent blocks were merged when they displayed multiallelic D 0 values above 0.95. Tagging SNPs were then selected both by their ability to represent haplotype diversity within these blocks down to the 10% haplotype frequency level and by their predicted ability to form reliable assays on the genotyping platform provided by Illumina Inc. (San Diego, CA, USA). Sixty-eight such SNPs ( Figure  1 and Table 1 ) were chosen over a span of 932 kb to cover the locus (including B24 kb 5 0 and B42 kb 3 0 of the 862 kb transcribed gene). These SNPs were typed at Illumina Inc., using their proprietorial bead-array technology on 368 bipolar disorder cases, 386 schizophrenia cases and 455 controls. Subsequent to the initial analysis and based on additional data released to the HapMap database, we chose two additional SNPs (numbers 14; rs4143873 and 16; rs7141245; Figure 1 and Table 1 ) to generate further haplotype information within the LD block containing SNP 15. This genotyping was carried out on the same DNA samples but at the Wellcome Trust Clinical Research Facility (Edinburgh, UK) using ABI TaqMan Assays on Demand (Applied Biosystems, Warrington, UK). These genotyping data were merged with the Illumina genotyping data and re-analysed.
The provenance of the DNA samples has been described elsewhere, [23] [24] [25] [26] but, in brief, it comprises patients of hospitals in southeast and south central Scotland and controls of matching geographical distribution obtained primarily from the Scottish National Blood Transfusion Service. Case diagnoses were made according to the DSM-IV criteria, based on case note review and interview using The Schedule for Affective Disorders and Schizophrenia-lifetime version (SADS-L). Final diagnoses were reached by consensus between two experienced psychiatrists (DHB and WJM). Informed consent was obtained from all individuals, and this work was approved by the Multi-Centre Research Ethics Committee for Scotland. Analyses carried out by us and other groups on the Scottish population suggest that it is generally stable and homogeneous, with no obvious evidence for substructure.
Genotyping quality and Hardy-Weinberg equilibrium NPAS3 was just one gene in a large commissioned genotyping project carried out at Illumina Inc. (comprising more than 700 SNPs and resulting in data that have already resulted in published association studies of the GRIK4, NRG1 and DISC1 genes and a region of chromosome 4). [23] [24] [25] [26] Overall, the quality and reproducibility of this genotyping was extremely high-the proprietary quality assessment score ('GenCall') was high for every analysed NPAS3 SNP marker. Moderate deviation from the Hardy-Weinberg equilibrium was observed for four markers in the control group, but in no instance did these correspond to significant P-values in the case-control analysis (Table 1) . Only associated region 3 (see the Results section) could potentially have been affected, but significant global and individual haplotype P-values were obtained for this region, which did not include the affected SNP.
Statistical analysis
Formatted genotype data were analysed using Cocaphase 27 to derive P-values for both single-marker associations and two-, three-and four-marker global and individual haplotype tests.
Cocaphase applies the expectation-maximization (EM) algorithm to estimate the haplotype frequencies of phase-unknown genotype data and performs standard unconditional logistic regression analysis, applying the likelihood ratio test under a log-linear model to compare haplotype frequencies between cases and controls. To avoid misleading global haplotype results caused by rare haplotypes, all haplotypes with a frequency less than or equal to 1% in both the cases and the controls were declared as rare and clumped together for the test of the null hypothesis using the command line option '-rare 0.01'. P-values for both global and individual tests of haplotype frequencies were determined. The global test P-value assesses the significance of the overall difference in the distribution of haplotype frequencies between cases and controls. The P-value from the individual test represents the significance of the difference in frequency of an individual haplotype relative to all the rest of the haplotypes between cases and controls. Odds ratios (ORs) were calculated online.
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Combinatorial analysis An additional subjective, conservative selection of SNP markers was made to permit definition of each of the four susceptibility and four protective haplotypes (henceforth termed the 'core associated regions'-CARs) identified within the NPAS3 gene (see Tables 1  and 2 ). Using the PHASE program 29, 30 under default parameters, we selected the most likely haplotype pairs at all CARs for each individual with the assumptions that neither precise CAR choice nor false-positive/false-negative haplotype assignments would be biased between case and control groups. The net genetic load was calculated by summing the number of protective (each given a À1 value) and susceptibility (each given a þ 1 value) haplotypes predicted to be present in each individual. The assignment of a unitary ± effect to each core haplotype is a justified approximation because of the similarity of the calculated ORs (as a measure of risk effect size) for all eight CAR haplotypes (data not shown).
The subsequent analyses included a T-test on mean net genetic load scores between case and control groups and calculation of sensitivity and specificity scores at each point (termed a 'cutoff') along the distribution.
Binary logistic regression
The effect of net genetic load at each CAR on risk was estimated using binary logistic regression, without adjustment for covariates. Diagnoses of combined schizophrenia and bipolar disorder or schizophrenia and bipolar separately were entered as the dependent variable. Subsequently, two binary logistic regression models were used to examine the independent effects of the polymorphisms on risk for each dependent variable. Model 1 contained all of the CARs as covariants in a model included only the main effects of the four regions. The second model (combined effects) included the main effects (block 1, enter) and all possible interactions (two-way, three-way, and four-way interactions) in a forward selection procedure. This model retained all interactions that were significant (P < 0.05) after adjustment for the main effects of all polymorphisms. For all models, the ORs and 95% confidence limits were calculated. For the model containing both main effects and significant interactions, the percentage of variability explained was calculated. Statistical analyses were performed using SPSS software (version 14.0; SPSS Inc., Chicago, IL, USA).
Results
Seventy SNPs were typed in 455 controls, 368 individuals with bipolar disorder and 386 individuals with schizophrenia (Table 1 and Figure 1 ). Singlemarker analysis identified five SNPs with significant deviations in frequency between single or combined case groups when compared to controls (SNP9, P = 0.0124; SNP15, P = 0.0062; SNP25, P = 0.0236; SNP37, P = 0.0161; and SNP56, P = 0.0315). With the exception of SNP9, these markers also contribute to significant global haplotype P-values ( Table 1 ) that appear to define four regions (henceforth denoted association regions 1-4) of significant association with schizophrenia, bipolar disorder or, in some cases, both diagnoses combined. Of particular note are a two-SNP region 1 global haplotype (SNPs 14 and 15) associated with bipolar disorder (P = 0.0063), a three-SNP region 2 global haplotype (SNPs 25-27) associated with combined diagnoses (P = 0.0046), a four-SNP region 3 global haplotype (SNPs 37-40) associated with schizophrenia (P = 0.0072) and two four-SNP region 4 global haplotypes (SNPs 54-57 and SNPs 55-58) associated with the combined Figure 1 Schematic representation of the NPAS3 locus including the position of the 12 exons, 70 genotyped SNPs and the predicted LD block structure across the gene. Also indicated are the four CARs studied in the combinatorial analyses, evolutionarily ultraconserved (uc) sequence blocks 21 and a sequence region showing human accelerated evolution (HAR). 22 CAR, core associated region; LD, linkage disequilibrium; NPAS3, neuronal PAS domain 3; SNP, single-nucleotide polymorphism.
NPAS3 association with schizophrenia and bipolar disorder BS Pickard et al For each region, the most significant individual haplotypes are shown for the combined case group as well as the bipolar disorder and schizophrenia groups separately. Cocaphase EM algorithm-predicted haplotype frequencies in the case and control groups are shown, together with mode of haplotype action (SUSC. and PROT.) and calculated P-value (most significant values are in bold). The resulting eight 'core' haplotypes used in the subsequent analyses are in bold. Italic letters are the constituent haplotypes summarized by the bold 'core' haplotypes. (P = 0.0020) and bipolar disorder (P = 0.0035) diagnoses, respectively. To investigate these four regions further, we examined the individual haplotype P-values calculated by Cocaphase (Table 2 ). An intriguing finding was that for each region, both susceptibility (higher frequency in case populations) and protective (higher frequency in control population) individual haplotypes were observed. The most significant individual susceptibility and protective haplotypes (listed with ORs and confidence intervals (CIs)) for each region were as follows: region 1: susceptibility to bipolar disorder: markers 15 and 16 (AT), P = 0.0016, OR = 1.3974 (95% CI: 1.1352-1.7202), and protection against bipolar disorder: markers 14 and 15 (TT), P = 0.0014, OR = 0.7107 (95% CI: 0.5772-0.8750); region 2: susceptibility to bipolar disorder: markers 25-27 (GTA), P = 0.0027, OR = 1.6809 (95% CI: 1.2699-2.2249), and protection against combined phenotypes: markers 25-27 (CCC), P = 0.0071, OR = 0.7184 (95% CI: 0.5890-0.8762); region 3: susceptibility to combined phenotype, markers 35-38 (CAGC), P = 0.0097, OR = 1.5697 (95% CI: 1.1627-2.1191), and protection against schizophrenia, markers 35-37 (CAC), P = 0.0187, OR = 0.7094 (95% CI: 0.5469-0.9202); region 4: susceptibility to combined phenotype, markers 54-56 (GCT), P = 0.0012, OR = 1.4328 (95% CI: 1.1715-1.7524), and protection against combined phenotype, markers 54-57 (GCGC), P = 0.0038, OR = 0.7449 (95% CI: 0.6285-0.8829). When either susceptibility or protective individual haplotypes with significant P-values were aligned across diagnostic boundaries, it was possible to construct larger contiguous underlying haplotypes for each region (Table 2 ). This formed the basis for the selection of eight CAR haplotypes (four susceptibility and four protective), which were studied in greater detail.
While the individual haplotype findings for the four regions are only moderately significant (and did not remain significant after permutation-based correction for multiple testing; data not shown) and of small effect size, there existed the possibility that they act in a combinatorial manner to determine an NPAS3-specific component of psychiatric illness risk. We applied the PHASE program to predict the most probable CAR haplotypes at each region for each individual. For every individual, the number of protective haplotypes present (maximum eight in the case of an individual homozygous at each of the four regions) was subtracted from the number of susceptibility haplotypes present to give a positive or negative number termed the 'net genetic load'.
In the first analysis (Figure 2, left) , the mean net genetic load and corresponding standard error of the mean were calculated and plotted for the control, bipolar disorder and schizophrenia groups. Twotailed, homoscedastic T-tests showed that both bipolar disorder and schizophrenia case mean net genetic loads were significantly higher (P = 0.0000010 and P = 0.0000012, respectively) than the control mean net genetic load. This finding is essentially a restatement of the original association findings but takes all four regions into account simultaneously and is therefore a gene-wide assessment of NPAS3 contribution to the risk of psychiatric illness in the general population. We subsequently repeated the initial analysis after removing all outlier individuals with a net genetic load of À5 or less or þ 4 or more (n = 27). We reasoned that it was possible that the significant differences between case and control mean net genetic loads might have been due to the disproportionate influence of outlier individuals. However, the revised mean net load values (Figure 2 , right) remained significantly different between cases and controls (T-tests as before: bipolar disorder, P = 0.0005035 and schizophrenia, P = 0.0000347), leading us to the conclusion that the net genetic load effect is a property of the entire population. Moreover, as a corollary, the diagnostic power of extreme net genetic load values (see below) could not have been directly predicted by the original positive casecontrol association findings in the population.
Secondly, as an objective verification of the individual and combined contributions of the CARs to disease risk, we carried out binary logistic regression analysis. A combined case group (schizophrenia and Figure 2 The mean net genetic load of the NPAS3 CAR haplotypes for all individuals with bipolar disorder or schizophrenia compared to controls (left) and the same analysis excluding individuals with extreme net genetic loads of À5 or less or þ 4 or more (right). Two-tailed T-tests showed that in both instances, the individuals with bipolar disorder or schizophrenia had a highly significantly different net genetic load as compared to controls (see the Results section), indicating strong gene-wide effect of the NPAS3 haplotypes on population disease risk. These data also suggest that outliers are not solely responsible for the statistical significance. CAR, core associated region; NPAS3, neuronal PAS domain 3. bipolar disorder) was used as the dependent variable with the separate net genetic load values at each of the four CARs entered as covariants. Individually, CARs 2, 3 and 4 significantly influenced disease status (model P-values 0.032, 0.006 and 0.005, respectively). When all four CARs were entered into the analysis, a model P-value of 0.00025 was obtained. A second model assessing the effect of all possible CAR interactions on the significance of the model retained only one interaction significant over and above the main effects of the CARs themselves. In the combined case group, the three-way CAR1, CAR3 and CAR4 interaction was retained giving a highly significant model P-value of 0.000085. Overall, the second model correctly classified disease status in 63% of individuals explaining 1.67% of the variability. This latter figure might be increased under a broader model that does not reduce the number of independent variables by preselecting CARs or summarizing haplotype data by means of the net genetic load score. Individually, CARs 2, 3 and 4 behaved in a risk-increasing manner (OR = 1.169 (95% CI: 1.014-1.348), OR = 1.233 (95% CI: 1.051-1.446), OR = 1.18 (95% CI: 1.047-1.33)). However, the CAR1-CAR3-CAR4 interaction component of the model was protective in action (OR = 0.78 (95% CI: 0.62-0.981)).
Similar findings were observed using either schizophrenia or bipolar disorder as the dependent variable, with one interaction variable being retained in the final model for each. For schizophrenia, the same three-way CAR1-CAR3-CAR4 interaction was retained giving a model P-value of 0.00038. For bipolar disorder, however, the three-way CAR1-CAR2-CAR4 interaction was retained with a model P-value of 0.00080.
In a third analysis, all individuals were grouped according to their net genetic load value (theoretically in a range between À8 and þ 8, with an additional 'null' group identified containing none of the risk/ protective haplotypes for NPAS3). The relative contributions of individuals from the control, bipolar disorder and schizophrenia groups were plotted for each net genetic load score (Figure 3 ). This plot indicated that progressing from low (minus) net genetic load values to high (positive) values was correlated with an increase in the proportions of both psychiatric diagnoses. Although the extremes of net genetic load are defined by few individuals (due to fewer haplotype permutations giving rise to such values), the pronounced skewing of their diagnoses (À6, all controls; þ 5, all cases) is remarkable. Moreover, we believe that this third analysis, concerning the effects of genotype assessed in individuals rather than populations, is an additional confirmation of the significance of the initial association study findings.
Finally, the predictive power of the net genetic load across its full range was visualized by plotting sensitivity and specificity scores (Figure 4 ). This confirmed that the cutoffs with the greatest diagnostic value were at the extremes of the distribution.
Discussion
We previously described a familial t(9,14)(q34.2;q13) chromosomal translocation, which disrupted the Figure 3 The net genetic load of the NPAS3 haplotypes affects the relative likelihood of diagnostic outcomes. Individuals with a defined net load value were categorized and the relative proportions of their case and control diagnoses plotted in the form of a stacked histogram. The 'null' category includes individuals with none of the susceptibility/protective haplotypes. Numbers of individuals in the respective load categories were 5, 11, 52, 99, 217, 259, 247, 168, 103, 25, 9, 2 and 12. NPAS3, neuronal PAS domain 3. Figure 4 Sensitivity and specificity plots as measures of the diagnostic power of 11 tests across the range of net genetic load values. Individuals were divided according to cutoff points shown on the x axis (e.g., À2/À1 indicates a comparison between individuals with a net genetic load of À2 or less and those with a net genetic load of À1 or more). The sensitivity plot reflects the accuracy of case prediction, whereas the specificity plot indicates the power to exclude controls. The accuracy of each measure is influenced by the test cutoff point selected-the high specificity at low load values highlights the protective haplotype effects. This is in contrast to the sensitivity measure, which is greatest when a high load cutoff value is selected-a consequence of susceptibility haplotype action.
NPAS3 gene leading to predicted haploinsufficiency. Here, we have shown by means of a case-control association study that distinct low penetrance susceptibility and protective alleles also exist for NPAS3. Significant single-marker, global haplotype and individual haplotype P-values were identified, defining four regions that contribute to altered risk. The alleles in these four regions, although displaying some relative differences in contribution to individual case groups, were all associated to some degree with both schizophrenia and bipolar disorder diagnoses, suggesting that their mode of action is one of the altered predispositions to psychotic illness in the general population. This is a property shared with other candidate genes (for example, NRG1
24 and DISC1
25
) and overlapping linkage hotspots, 31 which may reflect their role in more fundamental biological processes within the brain-with environmental and other genetic influences dictating the precise clinical end point.
Our results require replication in other sample sets, particularly in light of the failure of the individual markers to stand up to correction for multiple testing. However, our results suggest that these markers exhibit their true power only when examined in concert. This was revealed by comparing the net genetic load averages between cases and controls, assessing the interactions through logistic regression and examining the distribution of case and control individuals by net genetic load score.
Several recent studies have also identified interacting alleles in the context of altered risk of complex genetic disorders. Wu et al. 32 showed that a multigenic analysis of DNA-repair and cell-cycle control genes was efficient at predicting an individual's risk of bladder cancer. Johnson et al. 33 demonstrated that a combinatorial study of marginally significant risk alleles in candidate genes was efficient at predicting an individual's risk of breast cancer. Maller et al. 34 described the additive action of risk alleles of the CFH, LOC387715 and CFB/C2 loci in genetic susceptibility to age-related macular degeneration. Finally, and most relevant to this study, Baum et al., 35 in their recent genome-wide association study of bipolar disorder, carried out a similar analysis, adding together the risk alleles of the identified genes to create a value for each individual, which showed enhanced predictive power at the extreme of the distribution.
These reports raise the possibility that a proportion of individuals may have predictable psychiatric illness based solely on the assessment of the net genetic load of a set of alleles (a 'meta-diplotype') located within a relatively limited number of genes. With an ever-increasing list of candidate disease genes and alleles capable of refining the sensitivity of such an approach, its implications for genetic counselling infrastructure and ethics may need to be addressed.
